Loading
A phase 2 trial of Tucatinib, Eribulin and Trastuzumab in advanced solid tumours, run by Criterium, Inc., active and no longer recruiting.
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC is a phase 2 interventional study registered as NCT05458674 by Criterium, Inc., with 17 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2027-06-01. Interventions recorded: Tucatinib, Eribulin and Trastuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Criterium, HER2 tyrosine kinase inhibitors, Tucatinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Criterium and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/